Erectile dysfunction (ED) is the inability to achieve or maintain satisfactory erection of penis during sexual intercourse. It is usually an age related condition but can also be triggered by psychological factors. It may occur due to various reasons such as smoking, sedentary lifestyle and administration of certain drugs such as antidepressants, psychotropic drugs, antihypertensive and recreational drugs. Presently, oral phosphodiesterase type 5 inhibitors (PDE 5) commonly form the first line of treatment prescribed by doctors for ED. These include drugs namely, Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil) and Zydena (udenafil). The demand for erectile dysfunction drugs is high and is continuously rising as it caters to the needs of the growing elderly population and the high incidence rates of chronic disorders comprising hypertension, renal diseases and diabetes, neurological disorders and hormonal insufficiencies.
Erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the forecast period, i.e. by 2019, due to patent expiration of the key revenue generating drug Viagra outside the U.S. in 2013. In addition, Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG are also scheduled to lose their patent exclusivities during the forecast period. The loss of patent and marketing exclusivity will lead to a drastic reduction in revenues and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. Moreover, low success rate of novel drug formulations owing to weak pipeline development will also account for the downturn of the overall erectile dysfunction drugs market.
Pfizer’s Viagra was the largest revenue generator in 2012, in the total market, owing to its foremost presence in the pharmaceutical market for erectile dysfunction treatment. Viagra has maintained its blockbuster status till date, recording billion dollar sales every year for Pfizer, Inc. The primary competitors on the market for Viagra are Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG.
Geographically, North America dominated the global erectile dysfunction drugs market and is expected to continue to lead in terms of revenue generation throughout the forecast period. North America is considered as the most lucrative market for erectile dysfunction drugs owing to the presence of blockbuster drugs Viagra and Cialis in the U.S. market through 2019. The North American market for erectile dysfunction drugs was valued at USD 2,098.4 million in the year 2012. However, loss of patent exclusivities for Cialis (tadalafil) and Levitra/Staxyn (vardenafil) within the forecast period are expected to hamper market growth, though to a lesser extent. Factors such as increased market consolidation (due to influx of generics and weak pipeline development), cost containment measures coupled with introduction of cheaper products will result in rapid adoption of these drugs in the emerging markets. The leading players in the market for branded erectile dysfunction drugs are Pfizer, Inc., Eli Lilly & Co., Bayer AG, Dong-A Pharmaceutical Co. Ltd and Vivus, Inc.
The global erectile dysfunction drugs market is set to decline in the coming few years. The report on the global market for erectile dysfunction drugs market delivers an in-depth analysis of the trends responsible for the decline of this market. Additionally, the report provides statistical support to elaborate on the market’s decline.
The global erectile dysfunction drugs market report provides a 360-degree view of the treatments available in the market for erectile dysfunction (ED). These are localized therapy, vacuum constriction devices, PDE 5 inhibitors, testosterone replacement therapy, and alternative medicines. According to brand, the global erectile dysfunction drugs market is divided into Viagra, Cialis, Stendra/Spedra, Levitra/Staxyn, MUSE, Zydena, Mvix, and Helleva.
The global erectile dysfunction drugs market research report also evaluates pipeline drugs such as Vitaros, Uprima, and others. Geography-wise, the global erectile dysfunction drugs market is segmented into North America, Europe, Asia Pacific, and Rest of the World. Furthermore, the report also provides strategic recommendations such as cost containment measures, novel drug formulations owing to patent expirations of well-known ED drugs, and M&A tactics to strengthen market presence.
Overview of the global erectile dysfunction drugs market
Factors such as the growing elderly population, increasing awareness and patient education, elevated inclination towards a sedentary lifestyle, and growing incidence of several genitourinary diseases are expected to drive the growth of the global erectile dysfunction drugs market. Nevertheless, factors such as growing threat from counterfeit drugs, prevalence of STDs in ED drug users, and diminishing insurance coverage for ED treatment will greatly hamper the growth of the market.
The global erectile dysfunction drugs market will decelerate at a CAGR of 4.5% during the forecast period of 2013 to 2019. In 2012, the global erectile dysfunction drugs market stood at US$4.3 billion and is expected to reach a market value of US$3.4 billion by end of 2019. The North American erectile dysfunction drugs market held substantial market revenue of US$2,098.4 million in 2012.
The top three erectile dysfunction drugs in the market are Cialis (tadalafil), Staxyn/Levitra (vardenafil), and Viagra (sildenafil citrate). In 2013, Viagra held the largest market share of 45% in the global erectile dysfunction drugs market. The patent expiration of Viagra, especially outside the U.S., in 2013, along with the loss of patent and marketing exclusivity of the drug Levitra from Bayer AG and Cialis from Eli Lilly in Europe and other countries will result in the market’s steady decline.
Nevertheless, the extended patent exclusivity of Viagra till 2020 is anticipated to allow this brand to hold a major market revenue share in the U.S. The market for Cialis is also predicted to demonstrate a decline in revenue during the forecasting horizon. In 2012, Cialis was the second largest drug segment in the global ED drugs market, with revenue of US$1,926.8 million. However, the market for this drug will decline at a 12.6% CAGR during the forecast period.
Companies mentioned in the research report
Players in the market will tap on the opportunity of novel molecule combinations and innovative drug delivery techniques. The most established companies in the global erectile dysfunction drugs market are Bayer AG, Apricus Biosciences, Dong-A Pharmaceutical, Meda Pharmaceuticals, Eli Lilly And Company, Pfizer, Vivus, and S.K. Chemicals.
Major geographies analyzed under this research report are:
- North America
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments